Лики маниакально-депрессивного расстройства

Список литературы

1. Adli M., Hollinde D.L., Stamm T. et al. Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta- 50T/C single nucleotide polymorphism. Biological Psychiatry 2007; 62: 1295–1302.

2. Agid O., Shapira B., Zislin J. et al. Environment and vulnerability to major psychiatric illness: a case control study of early parental loss in major depression, bipolar disorder and schizophrenia. Molecular Psychiatry 1999; 4: 163–172.

3. Akiskal H.S. The clinical necessity of a return to Kraepelin’s broad schema of manic depression. Psychiatric Clinics of North America 1999; 22: xi-xii.

4. Akiskal K.K., Akiskal H.S. The theoretical underpinnings of affective temperaments: implications for evolutionary foundations of bipolar disorder and human nature. Journal of Affective Disorders 2005; 85: 231–239.

5. Allilaire J.F., Hantouche E.G., Sechter D. et al. Frequency and clinical aspects of bipolar II disorder in a French multicenter study: EPIDEP L’Encephale 2001; 27: 149–158.

6. Altamura A.C., Salvadori D., Madaro D. et al. Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: preliminary evidence from a 12-month open-label study. Journal of Affective Disorders 2003; 76: 267–271.

7. Amsterdam J.D, Shults J. Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study. International Clinical Psychopharmacology 2005; 20: 257–264.

8. Ando N., Morimoto K., Watanabe T. et al. Enhancement of central dopaminergic activity in the kainate model of temporal lobe epilepsy: implication for the mechanism of epileptic psychosis. Neuropsychopharmacology 2004; 29: 1251–1258.

9. Andreasen N.C. Creativity and mental illness: Prevalence rates in writers and their first-degree relatives. American Journal of Psychiatry 1987; 144: 1288–1292.

10. Andreasen N.C. Brave New Brain. Conquering Mental Illness in the Era of the Genome. Oxford University Press, Oxford, 2001.

11. Andreasen N.C. The Creating Brain. The Neuroscience of Genius. Dana Press, New York, 2005.

12. Angst J. Recurrent brief depression. A new concept of depression. Pharmacopsychiatry 1990; 23: 63–66.

13. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. Journal of Affective Disorders 1998; 50: 143–151.

14. Angst J. Zur Ätiologie und Nosologie endogener depressiver Psychosen. Springer-Verlag, Berlin, 1966.

15. Angst J., Adolfsson R., Benazzi F. et al. The HCL-32: towards a selfassessment tool for hypo-manic symptoms in outpatients. Journal of Affective Disorders 2005; 88: 217–233.

16. Angst J., Gamma A., Lewinsohn P. The evolving epidemiology of bipolar disorder. World Psychiatry 2002; 1: 146–148.

17. Aphorisms by Hippocrates, Internet Classics Archive. http://classics.mit.edu/Hipocrates/ aphorisms.1.i.html

18. Arfvedson A. Untersuchungen einiger bei der Eisen Grube von Utö vorkommenden Fossilien und von einem darin gefundenen neuen feuerfesten Alkali. Schweiggers Journal für Chemie und Physik 1818; 22: 93-120.

19. Arystoteles. Dzieia wszystkie. Tom 4. Panstwowe Wydawnictwo Naukowe, Warszawa, 1990.

20. Baastrup P.C. The use of lithium in manic-depressive psychoses. Comprehensive Psychiatry 1964; 10: 396–408.

21. Baastrup P.C., Schou M. Lithium as a prophylactic agent. Its effect against recurrent depressions and manic-depressive psychosis. Archives of General Psychiatry 1967; 16: 162172.

22. Baillarger J. De la folie ä double forme. Annales Medico-Psychologiques 1854; 6: 367391.

23. Baldessarini R.J., Tondo L., Davis P. et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disorders 2006; 8: 625–639.

24. Barraclough B. Suicide prevention, recurrent affective disorder and lithium. British Journal of Psychiatry 1972; 121: 391–392.

25. Barron F. Barron-Welsh Art Scale. A Portion of the Welsh Figure Preference Test. Consulting Psychologists Press, Palo Alto, California, 1963.

26. Bartrop R., Luckhurst E., Lazarus L. et al. Depressed lymphocyte function after bereavement. Lancet 1977; 1: 834–836.

27. Bauer M.S., Mitchner L. What is a «mood stabilizer»? An evidence-based response. American Journal of Psychiatry 2004; 161: 3-18.

28. Baum A.E., Akula N., Cabanero M. et al. A genome-wide association study implicates dia-cylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Molecular Psychiatry 2007; publikacja internetowa z 8 maja (przed drukiem w kolejnym numerze pisma).

29. Belmaker R.H., Livne A., Agam G. Role of inositol-1-phosphatase inhibition in the mechanism of action of lithium. Pharmacology and Toxicology 1990; 66 (Suppl 3): 76–83.

30. Berridge M.J , Downes C.P , Hanley M.R. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989; 59: 411–419.

31. Bilikiewicz T. Psychiatria kliniczna. Wyd. V popr. i uzup. Panstwowy Zakiad Wydawnictw Lekarskich, Warszawa, 1973.

32. Blader J.C., Carlson G.A. Increased rates of bipolar disorder diagnoses among U.S. child, adolescent, and adult inpatients, 1996–2004. Biological Psychiatry 2007; 62: 107–114.

33. Bleuler E. Dementia praecox oder Gruppe der Schizophrenien. Deuticke, Leipzig, 1911.

34. Blum K., Braverman E.R., Wu S. et al. Association of polymorphisms of dopamine D2 receptor (DRD2), and dopamine transporter (DAT1) genes with schizoid/avoidant behaviors (SAB). Molecular Psychiatry 1997; 2: 239–246.

35. Borkowska A., Rybakowski J.K. Neuropsychological frontal lobe tests indicate that bipolar depressed patients are more impaired than unipolar. Bipolar Disorders 2001; 3: 88–94.

36. Breggin P.R., Breggin G.R. Talking Back To Prozac: What Doctors Aren’t Telling You About Today’s Most Controversial Drug. St. Martins Press, New York, 1995.

37. Broszkiewicz J. Doktor Twardowski. Czytelnik, Warszawa, 1979.

38. Brown S.M., Hariri A.R. Neuroimaging studies of serotonin gene polymorphisms: exploring the interplay of genes, brain, and behavior. Cognitive and Affective Behavioral Neuroscience 2006; 6: 44–52.

39. Bunney W.E. Jr., Davis J.M. Norepinephrine in depressive reactions. A review. Archives of General Psychiatry 1965; 13: 483–494.

40. Burch G.S., Pavelis C., Hemsley D.R., Corr P.J. Schizotypy and creativity in visual artists. British Journal of Psychology 2006; 97: 177–190.

41. Burton R. The Anatomy of Melancholy. What it is: With all the Kinds, Causes, Symptoms and Several Cures of It. New York Review of Books, New York, 2001.

42. Cade J.F. Lithium salts in the treatment of psychotic excitement. Medical Journal of Australia 1949; 36: 349–352.

43. Calabrese J.R, Bowden CL, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry 2003; 64: 1013–1024.

44. Calabrese J.R., Keck P.E., Macfadden W. et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. American Journal of Psychiatry 2005; 162: 1351–1360.

45. Calabrese J.R., Muzina D.J., Kemp D.E. Predictors of bipolar disorder risk among patients currently treated for major depression. Medscape General Medicine 2006; 8: 38.

46. Carlsson A., Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3metho-xytyramine and normetanephrine in mouse brain. Acta Pharmacologica and Toxicologica 1963; 20: 140–144.

47. Carlsson I., Wendt P.E., Risberg J. On the neurobiology of creativity. Differences in frontal activity between high and low creative subjects. Neuropsychologia 2000; 38: 873–885.

48. Carroll B.J. The dexamethasone suppression test for melancholia. British Journal of Psychiatry 1982; 140: 292–304.

49. Carson S.H., Peterson J.B, Higgins D.M. Decreased latent inhibition is associated with increased creative achievement in high-functioning individuals. Journal of Personal and Social Psychology 2003; 85: 499–506.

50. Caspi A., Sugden K., Moffitt T.E. et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386–389.

51. Chaffin E.C. Manic-Depression. Inter/face 14 electronic literary magazine. Winter 1997/ Spring 1998. http://www.albany.edu/~interfac/if14/c_e_chaffin.html

52. Cloninger CR. A systematic method for clinical description and classification of personality variants. A proposal. Archives of General Psychiatry 1987; 44: 573–588.

53. Colom F, Vieta E. Sudden glory revisited: cognitive contents of hypomania. Psychotherapy and Psychosomatics 2007; 76: 278–288.

54. Coppen A. Defects in monoamine metabolism and their possible importance in the pathoge-nesis of depressive syndromes. Psychiatria Neurologia Neurochirurgia 1969; 72: 173–180.

55. Coryell W, Endicott J, Keller M et al. Bipolar affective disorder and high achievement: a familial association. American Journal of Psychiatry 1989; 146: 983–988.

56. Cotard J. Du délire des negations. Archives de Neurologie 1882; 4: 152170.

57. Craddock N., Forty L. Genetics of affective (mood) disorders. European Journal of Human Genetics 2006; 14: 660–668.

58. Crick F. The Astonishing Hypothesis. The Scientific Search for the Soul. Touchstone, New York, 1995.

59. Crossley N.A., Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. Journal of Clinical Psychiatry 2007; 68: 935–940.

60. Darwin CR. The Expression of the Emotions in Man and Animals. John Murray, London, 1872.

61. Dawkins R. The Selfish Gene. Oxford Univeristy Press, Oxford, 1976.

62. De Montigny C, Grunberg F, Mayer A, Deschenes JP Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. British Journal of Psychiatry 1981; 138: 252–256.

63. Denicoff KD, Smith-Jackson EE, Disney ER et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. Journal of Clinical Psychiatry 1997; 58: 470–478.

64. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. DSM-IV American Psychiatric Association, Washington, DC, 1994.

65. Dickinson E. 100 wierszy (100 poems). Wydawnictwo Arka, Krakow, 1990.

66. Dmitrzak-Wçglarz M., Rybakowski J.K., Stopien A. et al. Dopamine receptor D1 gene-48A/G polymorphism is associated with bipolar illness but not with schizophrenia in a Polish population. Neuropsychobiology 2006; 53: 46–50.

67. Dowlatshahi D., MacQueen G.M., Wang J.F., Young L.T. Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet 1998; 352; 17541755.

68. Drôzdz W., Wojnar M., Araszkiewicz A. et al. Badanie rozpowszechnienia zaburzen depresyjnych u pacjentow podstawowejopieki zdrowotnej w Polsce. Wiadomosci Lekarskie 2007; 60: 109–113.

69. Duke P. Hochman G. A Brilliant Madness. Living with Manic-Depressive Illness. Bantam Books, New York, 1992.

70. Duke P. Turan K. Call Me Anna. The Autobiography of Patty Duke. Bantam Books, New York, 1987.

71. Duman R.S, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Archives of General Psychiatry 1997; 54: 597–606.

72. Dunner D.L, Amsterdam J.D., Shelton R.C. et al. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. Journal of Clinical Psychiatry 2007; 68: 10711077.

73. Dunner D.L., Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Archives of General Psychiatry 1974; 30: 229–233.

74. Dunner D.L., Gershon ES, Goodwin F.K. Heritable factors in the severity of affective illness. Biological Psychiatry 1976; 11: 31–42.

75. Egeland J.A., Gerhard D., Pauls D.L. et al. Bipolar affective disorders linked to DNA markers on chromosome 11. Nature 1987; 325: 783–787.

76. Einat H., Yuan P Szabo ST et al. Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 2007; 55: 123–131.

77. Falret J-P. Memoire sur la folie circulaire, forme de la maladie mentale caracterisee par la reproduction successive et reguliere de l’etat maniaque, de l’etat melancolique, et d’un intervalle lucide plus ou moins prolonge. Bulletin de l’Academie imperiale de medecine, Paris, 1854; 19: 382–400.

78. Figueroa C.G. Virginia Woolf: enfermedad mental y creatividad artistica. Revista me dica de Chile 2005; 133: 1381–1388.

79. Flaherty A.W. Frontotemporal and dopaminergic control of idea generation and creative drive. Journal of Comparative Neurology 2005; 493: 147–153.

80. Flaherty A.W. The Midnight Disease: The Drive to Write, Writer’s Block, and the Creative Brain. First Mariner Books, Boston – New York, 2005.

81. Folley B.S., Park S. Verbal creativity and schizotypal personality in relation to prefrontal hemispheric laterality: a behavioral and near-infrared optical imaging study. Schizophrenia Research 2005; 80: 271–282.

82. Frank E., Kupfer D.J., Thase M.E et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Archives of General Psychiatry 2005; 62: 996-1004.

83. Frazer A, Winokur A. (red.). Biologiczne podstawy zaburzen psychicznych. Panstwowy Zakiad Wydawnictw Lekarskich, Warszawa, 1982.

84. Freud S. Trauer und Melancholie. Fischer, Frankfurt, 1917.

85. Freud S., Breuer J. Studien über Hysterie. Franz Deuticke, Leipzig – Wien, 1895.

86. Garrod A.B. Gout and Rheumatic Gout. Walton and Maberly, London, 1858.

87. Gartner J.D. The Hypomanic Edge: The Link between (a Little) Craziness and (a Lot of) Success in America. Simon & Schuster, New York, 2005.

88. Ghaemi S.N., Ko J.Y., Goodwin F.K. The bipolar spectrum and the antidepressant view of the world. Journal of Psychiatric Practice 2001; 7: 287–297.

89. Gibb B.E., McGeary J.E., Beevers C.G., Miller I.W. Serotonin transporter (5-HTTLPR) genotype, childhood abuse, and suicide attempts in adult psychiatric inpatients. Suicide and Life Threatening Behavior 2006; 36: 687–693.

90. Gilbert P. Evolution and depression: issues and implications. Psychological Medicine 2006; 36: 287–297.

91. Glenmullen J. Prozac Backlash: Overcoming the Dangers of Prozac, Zoloft, Paxil, and Other Antidepressants with Safe, Effective Alternatives. Simon & Schuster, New York, 2001.

92. Golimbet V.E., Alfimova M.V., Gritsenko I.K, Ebstein R.P. Relationship between dopamine system genes and extraversion and novelty seeking. Neuroscience and Behavioral Physiology 2007; 37: 601–606.

93. Goodwin F.K., Jamison K.R. Manic-Depressive Illness. Oxford University Press, Oxford, 1990.

94. Goodwin F.K., Jamison K.R. Manic-Depressive Illness. Bipolar Disorders and Recurrent Depression. Second Edition. Oxford University Press, Oxford, 2007.

95. Gould T.D., Chen G., Manji H.K. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 2004; 29: 32–38.

96. Green E.K., Raybould R, Macgregor S et al. Genetic variation of brain- derived neurotrophic factor (BDNF) in bipolar disorder. British Journal of Psychiatry 2006; 188: 21–25.

97. Greil W., Kleindienst N, Erazo N, Müller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. Journal of Clinical Psychopharmaco-logy 1998; 18: 455–460.

98. Grof P. Excellent lithium responders: people whose lives have been changed by lithium prophylaxis. In: Birch NJ, Gallicchio VS, Becker RW (eds.). Lithium: 50 Years of Psycho-pharmacology, New Perspectives in Biomedical and Clinical Research. Weidner Publishing Group, Cheshire, Connecticut, 1999: 36–51.

99. Guilford J.P. The structure of the intellect. Psychological Bulletin 1956; 53: 267–293.

100. Hahn C.G, Umapathy C, Wang HY et al. Lithium and valproic acid treatments reduce PKC activation and receptor-G protein coupling in platelets of bipolar manic patients. Journal of Psychiatric Research 2005; 39: 355–363.

101. Hamilton W.D. Narrow Roads of Gene Land: The Collected Papers of WD. Hamilton. WH. Freeman/Spektrum, Oxford – New York, 1996.

102. Hardoy M.C., Garofalo A., Carpiniello B. et al. Combination quetiapine therapy in the long-term treatment of patients with bipolar I disorder. Clinical Practice and Epidemiology in Mental Health 2005; 1: 7.

103. Hariri A.R., Drabant E.M., Munoz K.E. et al. A susceptibility gene for affective disorders and the response of the human amygdala. Archives of General Psychiatry 2005; 62: 146–152.

104. Hartigan G.P. The use of lithium salts in affective disorders. British Journal of Psychiatry 1963; 109: 810–814.

105. Hauser J., Leszczynska A, Samochowiec J et al. Association analysis of the insertion/deletion polymorphism in serotonin transporter gene in patients with affective disorder. European Psychiatry 2003; 18: 129–132.

106. Hauser J., Leszczynska A, Samochowiec J et al. The association study of a functional polymorphism of the monoamine oxidase A gene promotor in patients with affective disorders. Archives of Psychiatry and Psychotherapy 2002; 4: 9-15.

107. Herbert Z. Pan Cogito. Czytelnik, Warszawa, 1974.

108. Heron J, Jones I, Williams J et al. Self-reported schizotypy and bipolar disorder: demonstration of a lack of specificity of the Kings Schizotypy Questionnaire. Schizophrenia Research 2003; 65: 153–158.

109. Heuser I, Yassouridis A, Holsboer F. The combined dexamethasone/ CRH test: a refined laboratory test for psychiatric disorders. Journal of Psychiatric Research 1994; 28: 341-56.

110. Hirschfeld R.M., Calabrese J.R., Weissman M.M. et al. Screening for bipolar disorder in the community. Journal of Clinical Psychiatry 2003; 64: 53–59.

111. Hirschfeld R.M., Lewis L., Vornik L.A. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. Journal of Clinical Psychiatry 2003; 64: 161–174.

112. Hirschfeld R.M., Williams J.B., Spitzer R.L. et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. American Journal of Psychiatry 2000; 157: 1873–1875.

113. Hoffmann H. Die Nachkommenschaft bei endogenen Psychosen. Springer-Verlag, Berlin, 1921.

114. Hoppe K.D. Hemispheric specialization and creativity. Psychiatric Clinic of North America 1988; 11: 303–315.

115. Hosak L. Role of the COMT gene Val158Met polymorphism in mental disorders. A review. European Psychiatry 2007; 22: 276–281.

116. Iitaka C., Miyazaki K., Akaike T., Ishida N. A role for glycogen synthase kinase-3beta in the mammalian circadian clock. Journal of Biological Chemistry 2005; 280: 29397-29402.

117. International Classification of Diseases. Tenth Edition. ICD-10. Classification of Mental and Behavioural Disorders. World Health Organization, Geneva, 1992.

118. Irwin M., Daniels M., Bloom E. et al. Life events, depressive symptoms and immune functions. American Journal of Psychiatry 1987; 144: 437–441.

119. Jamison K.R. An Unquiet Mind. A Memoir of Moods and Madness. Alfred A. Knopf, New York, 1996.

120. Jamison K.R. Exuberance. The Passion for Life. Alfred A. Knopf, New York, 2004.

121. Jamison K.R. Niespokojny umysł. Pamiętnik nastrojów i szaleństwa. Zysk i S-ka, Poznań, 2000.

122. Jamison K.R. Noc szybko nadchodzi. Zrozumieć samobójstwo, by mu zapobiec. Zysk i S-ka, Poznań, 2004.

123. Jamison K.R. Night Falls Fast. Understanding Suicide. Alfred A. Knopf, New York, 1999.

124. Jamison K.R. Touched with Fire. Manic-Depressive Illness and the Artistic Temperament. Free Press Paperback, New York, 1993.

125. Jayson L.M. Mania. Funk and Wagnalls, New York, 1937.

126. Jones S.H., Bentall R.P. The Psychology of Bipolar Disorder. New Development and Research Strategies. Oxford University Press, Oxford, 2006.

127. Kapur S., Mizrahi R., Li M. From dopamine to salience to psychosis – linking biology, pharmacology and phenomenology of psychosis. Schizophrenia Research 2005; 79: 59–68.

128. Kasanin J. The acute schizoaffective psychoses. American Journal of Psychiatry 1933; 90:97-126.

129. Kato T. Molecular genetics of bipolar disorder and depression. Psychiatry and Clinical Neu-rosciences 2007; 61: 3-19.

130. Keck P.E., Calabrese J.R., McIntyre R.S. et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. Journal of Clinical Psychiatry 2007; 68: 1480–1491.

131. Keller M.B., Shapiro R.W. «Double depression»: superimposition of acute depressive episodes on chronic depressive disorders. American Journal of Psychiatry 1982; 139: 438–442.

132. Keltikangas-Järvinen L., Elovainio M., Kivimäki M. et al. Association between the type 4 do-pamine receptor gene polymorphism and novelty seeking. Psychosomatic Medicine 2003; 65: 471–476.

133. Kępiński A. Melancholia. Państwowy Zaktad Wydawnictw Lekarskich, Warszawa, 1974.

134. Kluver H., Bucy P.C. Psychic blindness and other symptoms following bilateral temporal lobectomy. American Journal of Physiology 1937; 119: 352–353.

135. Knutson B., Rick S., Wimmer G.E. et al. Neural predictors of purchases. Neuron 2007; 53: 147–156.

136. Kochanowski J. Fraszki. Piesni. Treny. Wydawnictwo Zielona Sowa, Krakow, 2004.

137. Koukopoulos A. The primacy of mania. Annals of General Psychiatry 2006; 5 (Suppl 1): S5.

138. Koukopoulos A., Koukopoulos A. Agitated depression as a mixed state and the problem of melancholia. Psychiatric Clinic of North America 1999; 22: 547–564.

139. Kozikowski A.P., Gaisina I.N., Yuan H. et al. Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. possible new GSK-3beta therapies for bipolar disorders. Journal of American Chemical Society 2007; 129: 8328–8332.

140. Kraepelin E. Psychiatrie. Ein Lehrbuch für Studierende und Ärzte. 6 Auflage. Barth, Leipzig, 1899.

141. Kramer P.D. Listening to Prozac. Penguin Books, New York, 1993.

142. Kramer PD. Wsiuchujqc siç w Prozac. Przeiom w psychofarmakoterapii depresji. Wydawnictwo Jacek Santorski & Co, Warszawa, 1995.

143. KretschmerE. Körperbau und Charakter. Springer, Berlin, 1929.

144. Kuhn R. The treatment of depressive states with G 22355 (imipramine hydrochloride). American Journal of Psychiatry 1958; 115: 459–464.

145. Lambert P.A., Borselli S., Marcou G. et al. Long-term thymoregulative action of Depamide in manic-depressive psychoses. Annales Medico- Psychologiques 1971; 2: 442–448.

146. Lange C. Periodische Depressionzustände und ihre Pathogenesis auf dem Boden der harnsäuren Diathese. Verlag von Leopold Voss, Hamburg – Leipzig, 1896.

147. Lapin I.P, Oxenkrug G.F. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1969; 7586: 132–136.

148. Lauronen E., Veijola J., Isohanni I. et al. Links between creativity and mental disorder. Psychiatry 2004; 67: 81–98.

149. LeDoux J. The Emotional Brain. The Mysterious Underpinnings of Emotional Life. Simon & Schuster, New York, 1996.

150. Lee A.L., Ogle W.O., Sapolsky R.M. Stress and depression: possible links to neuron death in the hippocampus. Bipolar Disorders 2002; 4: 117128.

151. Leonhard K. Aufteilung der endogenen Psychosen und ihre differenzierte Ätiologie. Georg Thieme Verlag, Stuttgart – New York, 1995.

152. Lesch K.P., Bengel D., Heils A. et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527–1531.

153. Levy S., Sutton G, Ng P.C. et al. The diploid genome sequence of an individual human. PLoS Biology 2007; 5: e254.

154. Lombroso C. The Man of Genius. Contemporary Science Series, Charles Scribner’s Sons, New York, 1891.

155. Ludwig A.M. Creative achievement and psychopathology: comparison among professions. American Journal of Psychotherapy 1992; 46: 330356.

156. Ludwig A.M. Mental illness and creative activity in female writers. American Journal of Psychiatry 1994; 151: 1650–1656.

157. Luria S.E. A Slot Machine, a Broken Test Tube: An Autobiography. Harper and Row, New York, 1984.

158. Luxenburger H. Vorläufiger Bericht über psychiatrische Serienuntersuchungen an Zwillingen. Zeitschrift für die gesamte Neurologie und Psychiatrie 1928; 56: 297–326.

159. Lynn D.E., Lubke G., Yang M. et al. Temperament and character profiles and the dopamine D4 receptor gene in ADHD. American Journal of Psychiatry 2005; 162: 906–913.

160. MacLean P.D. Psychosomatic disease and the visceral brain: recent developments bearing on the Papez theory of emotion. Psychosomatic Medicine 1949; 11: 338–353.

161. Marino A. Widziaiem ciemne sionce. Pozegnanie depresji. Wydawnictwo Jacek Santorski & Co, Warszawa, 1995.

162. Marneros A., Angst J. Bipolar disorders: roots and evolution. In: Marneros A, Angst J (eds.). Bipolar Disorders. 100 Years After Manic Depressive Insanity. Kluwer Academic Publishers, Dordrecht, 2000: 1-35.

163. Marneros A., Goodwin F. (eds.). Bipolar Disorders. Mixed States, Rapid Cycling, and Atypical Forms. Cambridge University Press, Cambridge, 2005.

164. Martin E. Bipolar Expeditions. Mania and Depression in American Culture. Princeton University Press, Princeton & Oxford, 2007.

165. Massat I., Souery D., Del-Favero J. et al. Positive association of dopamine D2 receptor polymorphism with bipolar affective disorder in a European Multicenter Association Study of affective disorders. American Journal of Medical Genetics 2002; 114: 177–185.

166. Matkowski J., Rybakowski J. Karbamazepina w leczeniu zespoiow depresyjnych. Psychiatria Polska 1992; 26: 251–258.

167. Mayberg H.S., Lozano A.M., Voon V. et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005; 45: 651–660.

168. McDermott J.F. Emily Dickinson revisited: A study of periodicity in her work. American Journal of Psychiatry 2001; 158: 686–690.

169. McElroy S.L., Kotwal R., Keck P.E. Jr. Comorbidity of eating disorders with bipolar disorder and treatment implications. Bipolar Disorders 2006; 8: 686–695.

170. Meaney MJ, Aitken DH, van Berkel C et al. Effect of neonatal handling on age-related impairments associated with the hippocampus. Science 1988; 239: 766–768.

171. Mendel EE. Die Manie. Eine Monographie. VDM Verlag Dr. Müller, Saarbrücken, 2007. Reproduktion der Ausgabe von 1881.

172. Mendels J. Lithium in the treatment of depression. American Journal of Psychiatry 1976; 133: 373–378.

173. Mendlewicz J., Linkowski P. Guroff J.J., van Praag H.M. Color blindness linkage to bipolar manic-depressive illness. New evidence. Archives of General Psychiatry 1979; 36: 1442–1447.

174. Merikangas K.R., Akiskal H.S., Angst J. et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Archives of General Psychiatry 2007; 64: 543–552.

175. Merskey H. Anna O. had a severe depressive illness. British Journal of Psychiatry 1992; 161: 185–194.

176. Miklowitz D.J., Otto M.E., Frank E. et al. Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. American Journal of Psychiatry 2007; 164: 1340–1347.

177. Miller G.F. Aesthetic fitness: How sexual selection shaped artistic virtuosity as a fitness indicator and aesthetic preferences as mate choice criteria. Bulletin of Psychology and the Arts 2001; 2: 20–25.

178. Moore G.J., Bebchuk J.M., Wilds I.B. et al. Lithium-induced increase in human brain grey matter. Lancet 2000; 356: 1241–1242.

179. Muglia P. Petronis A., Mundo E et al. Dopamine D4 receptor and tyrosine hydroxylase genes in bipolar disorder: evidence for a role of DRD4. Molecular Psychiatry 2002; 7: 860–866.

180. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349: 1498–1504.

181. Müller-Oerlinghausen B., Müser-Causemann B., Volk J. Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. Journal of Affective Disorders 1992; 25: 261–269.

182. Nasierowski T. Historia zaburzen nastroju. Psychiatria w Praktyce Ogolnolekarskiej 2007; 7: 75–86.

183. Nesse R.M. Is depression an adaptation? Archives of General Psychiatry 2000; 57: 14–20.

184. Nesse R.M. The smoke detector principle. Natural selection and the regulation of defensive responses. Annales of the New York Academy of Sciences 2001; 935: 75–85.

185. Nesse R.M, Williams G.C. Evolution and Healing: The New Science of Darwinian Medicine. Phoenix, London, 1996.

186. Nestler E.J, Carlezon W.A. Jr. The mesolimbic dopamine reward circuit in depression. Biological Psychiatry 2006; 59: 1151–1159.

187. Nettle D. The evolution of personality variation in humans and other animals. American Psychologist 2006; 61: 622–631.

188. Nettle D., Clegg H. Schizotypy, creativity and mating success in humans. Proceedings: Biological Sciences 2006; 273: 611–615.

189. Neves-Pereira M., Mundo E., Muglia P. et al. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. American Journal of Human Genetics 2002; 71: 651–655.

190. Norden M.J. Beyond Prozac. Harper Collins, New York, 1995.

191. Okuma T, Kishimoto A, Inoue K. Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis. A preliminary report. Folia Psychiatrica et Neurologica Japanica 1973; 27: 283–297.

192. Ortiz-Dominguez A, Hernandez ME, Berlanga C et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disorders 2007; 9: 596–602.

193. Osby U., Brandt L., Correia N. et al. Excess mortality in bipolar and unipolar disorder in Sweden. Archives of General Psychiatry 2001; 58: 844–850.

194. Panksepp J. Neuroscience. Feeling the pain of social loss. Science 2003; 302: 237–239.

195. Papez J.W. A proposed mechanism of emotion. Archives of Neurology and Psychiatry 1937; 38: 723–743.

196. Papolos D.F., Faedda G.L., Veit S. et al. Bipolar spectrum disorders in patients diagnosed with velo-cardio-facial syndrome: does a hemizygous deletion of chromosome 22q11 result in bipolar affective disorder? American Journal of Psychiatry 1996; 153: 1541–1547.

197. Passmore MJ, Garnham J, Duffy A et al. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disorders 2003; 5: 110–114.

198. Patil S.T., Zhang L., Martenyi F. et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Medicine 2007; 13: 11021107.

199. Pawlikowska-Jasnorzewska M. Poezje wybrane. Ludowa Spoidzielnia Wydawnicza, Warszawa, 1968.

200. Perlis R.H., Welge J.A., Vornik L.A. et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. Journal of Clinical Psychiatry 2006; 67: 509–516.

201. Perris C. A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. I. Genetic investigation. Acta Psychiatrica Scandinavica 1966; 194: 15–44.

202. Pezawas L., Meyer-Lindenberg A., Drabant E.M. et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nature Neuroscience 2005; 8: 828-34.

203. Pezawas L., Verchinski B.A., Mattay V.S. et al. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. Journal of Neuroscience 2004; 24: 10099-10102.

204. Post F. Creativity and psychopathology. A study of 291 world-famous men. British Journal of Psychiatry 1994; 165: 22–34.

205. Post F. Verbal creativity, depression and alcoholism. An investigation of one hundred American and British writers. British Journal of Psychiatry 1996; 168: 545–555.

206. Post R.M., Leverich G.S., Nolen W.A. et al. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network. Bipolar Disorders 2003; 5: 396–406.

207. Post R.M., Rubinow DR, Uhde T.W. et al. Dysphoric mania. Clinical and biological correlates. Archives of General Psychiatry 1989; 46: 353–358.

208. Puzynski S., Kalinowski A., Koszewska I. et al. Zasady leczenia nawracajgcych zaburzen afektywnych. Farmakoterapia w Psychiatrii i Neurologii 2004; 20: 5-46.

209. Puzynski S., KlosiewiczL. Valproic acid amide in the treatment of affective and schizoaffec-tive disorders. Journal of Affective Disorders 1984; 6: 115–121.

210. Rapaport M.H., Gharabawi G.M., Canuso C.M. et al. Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 2006; 31: 2505–2513.

211. Reuter M., Roth S., Holve K., Hennig J. Identification of first candidate genes for creativity: a pilot study. Brain Research 2006; 1069: 190–197.

212. Rihmer Z., Pestality P. Bipolar II disorder and suicidal behavior. Psychiatric Clinic of North America 1999; 22: 667–673.

213. Robertson G.M. Does mania include two distinct varieties of insanity and should be subdivided? Journal of Mental Science 1890; 36: 338–347.

214. Rosenthal N.E., Sack D., Gillin J.C. et al. Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Archives of General Psychiatry 1984; 41: 72–80.

215. Roybal K., Theobold D., Graham A. et al. Mania-like behavior induced by disruption of CLOCK. Proceedings of the National Academy of Sciences of the USA 2007; 104: 6406–6411.

216. Rybakowski J. Aripirazol – lek przeciwpsychotyczny trzeciej generacji. Ordynator Lekow 2006; 6: 17–20.

217. Rybakowski J. Dziatanie neuroprotekcyjne lekow przeciwdepresyjnych i normotymicznych. Neuropsychiatria i Neuropsychologia 2006; 1: 49–55.

218. Rybakowski J.K. New-Deli: a twelve-week, open, randomized trial comparing sodium val-proate to lithium in patients with bipolar 1 disorder. European Neuropsychopharmacology 2006; 16 (Suppl 4): S352.

219. Rybakowski J. The antidepressant effect of carbamazepine in callosal agenesis: a case report. Pharmacopsychiatry 1992; 25: 154–156.

220. Rybakowski J.K. Two generations of mood stabilizers. International Journal of Neuropsycho-pharmacology 2007; 10: 709–711.

221. Rybakowski J. Zaburzenia psychiczne w swietle koncepcji ewolucji i socjobiologii. In: Bili-kiewicz A, Puzynski S, Rybakowski J, Wciorka J. (eds.). Psychiatria. Tom 1. Wydawnictwo Medyczne Urban & Partner, Wroclaw, 2002: 224–234.

222. Rybakowski J.K., Amsterdam JD. Lithium prophylaxis and recurrent labial herpes infections. Lithium 1991; 2: 43–47.

223. Rybakowski J.K., Borkowska A, Czerski PM et al. Polymorphism of the brain-derived neu-rotrophic factor gene and performance on a cognitive prefrontal test in bipolar patients. Bipolar Disorders 2003; 5: 468–472.

224. Rybakowski J.K., Borkowska A, Skibinska M, Hauser J. Illness-specific association of val66met BDNF polymorphism with performance on Wisconsin Card Sorting Test in bipolar mood disorder. Molecular Psychiatry 2006; 11: 122–124.

225. Rybakowski J., Chlopocka-Wozniak M. Dlugotrwale stosowanie wçglanu litu – refleksje na podstawie przypadku 25-letniej profilaktyki litem. Psychiatria Polska 1996; 30: 731–740.

226. Rybakowski J., Chlopocka-Wozniak M., Kapelski Z. Ocena kliniczna skutecznosci profilaktycznej dlugotrwalego stosowania wçglanu litu u chorych z endogennymi zespolami depresyjnymi. Psychiatria Polska 1980; 14: 357–361.

227. Rybakowski J.K, Chlopocka-Wozniak M., Suwalska A. The prophylactic effect of long-term lithium administration in bipolar patients entering treatment in the 1970s and 1980s. Bipolar Disorders 2001; 3: 63–67.

228. Rybakowski J., Dudek D., Jaracz J. et al. Standardy leczenia chorob afektywnych. Farmakoterapia w Psychiatrii i Neurologii 2007; 23: 7-61.

229. Rybakowski J., Frazer A., Mendels J., Ramsey T.A. Erythrocyte accumulation of the lithium ion in control subjects and patients with primary affective disorder. Communications in Psycho-pharmacology 1978; 2: 99-104.

230. Rybakowski J., Matkowski K. Adding lithium to antidepressant therapy: factors related to therapeutic potentiation. European Neuropsychopharmacology 1992; 2: 161–165.

231. Rybakowski J., Matkowski K. Synergistyczne dzialanie litu i tymoleptykow w depresji endogennej. Psychiatria Polska 1987; 21: 115–120.

232. Rybakowski J.K., Suwalska A, Chlopocka-Wozniak M. Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression. Neuropsychobiology 1999; 40:134–139.

233. Rybakowski J.K., Suwalska A, Czerski PM et al. Prophylactic effect of lithium in bipolar affective illness may be related to serotonin transporter genotype. Pharmacological Report 2005; 57: 124–127.

234. Rybakowski J.K., Suwalska A, Lojko D et al. Bipolar mood disorders among Polish psychiatric outpatients treated for major depression. Journal of Affective Disorders 2005; 84: 141–147.

235. Rybakowski J.K., Suwalska A, Lojko D et al. Types of depression more frequent in bipolar than in unipolar affective illness: results of the Polish DEP-BI study. Psychopathology 2007; 40: 153–158.

236. Rybakowski J.K., Suwalska A, Skibinska M et al. Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry 2005; 38: 166–170.

237. Rybakowski J., Tuszewska M. Lithium or lamotrigine augmentation in treatment-resistant depression. International Journal of Neuropsychopharmacology 2006; 9 (Suppl 1): S232.

238. Rybakowski J.K., Twardowska K. The dexamethasone/corticotropin- releasing hormone test in depression in bipolar and unipolar affective illness. Journal of Psychiatric Research 1999; 33: 363–370.

239. Rybakowski J.K., Wykrçtowicz A, Heymann-Szlachcinska A, Wysocki H. Impairment of endo-thelial function in unipolar and bipolar depression. Biological Psychiatry 2006; 60: 889–891.

240. Sachar E.J., Hellman L., Roffwarg H.P. et al. Disrupted 24-hour patterns of cortisol secretion in psychotic depression. Archives of General Psychiatry 1973; 28: 19–24.

241. Saggese J., Lieberman D.Z., Goodwin F.K. The role of recurrence and cyclicity in differentiating mood disorder diagnoses. Primary Psychiatry 2006; 13: 43–48.

242. Sajatovic M., Valenstein M., Blow F. et al. Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder. Psychiatric Services 2007; 58: 855–863.

243. Santosa C.M., Strong C.M., Nowakowska C. et al. Enhanced creativity in bipolar disorder patients: a controlled study. Journal of Affective Disorders 2007; 100: 31–39.

244. Scheffer R.E. Concurrent ADHD and bipolar disorder. Current Psychiatry Reports 2007; 9: 415–419.

245. Schildkraut J.J. The catecholamine hypothesis of affective disorders: A review of the supporting evidence. American Journal of Psychiatry 1965; 122: 509–522.

246. Schildkraut J.J., Hirshfeld A.J., Murphy J.M. Mind and mood in modern art, II: Depressive disorders, spirituality, and early deaths in the abstract expressionist artists of the New York School. American Journal of Psychiatry 1994; 151: 482–488.

247. Schneider K. Klinische Psychopathologie. Georg Thieme Verlag, Stuttgart, 1950.

248. Schou M. Artistic productivity and lithium prophylaxis in manic-depressive illness. British Journal of Psychiatry 1979; 135: 97-103.

249. Schou M. Biology and the pharmacology of lithium ion. Pharmacological Reviews 1957; 9: 17–58.

250. Schou M. Lit w leczeniu chorob afektywnych. Instytut Psychiatrii i Neurologii, Warszawa, 2006.

251. Schou M, Juel-Nielsen N, Stromgren E, Voldby H. The treatment of manic psychoses by the administration of lithium salts. Journal of Neurology Neurosurgery and Psychiatry 1954; 17: 250–260.

252. Schou M., Thompsen K. Lithium prophylaxis of recurrent endogenous affective disorders. In: Johnson FN (eds.). Lithium Research and Therapy. Academic Press, London, 1976: 63–84.

253. Schuldberg D. Eysenck Personality Questionnaire scales and paper-and-pencil tests related to creativity. Psychological Report 2005; 97: 180–182.

254. Seeman P. Brain dopamine receptors. Pharmacological Reviews 1980; 32: 229–313.

255. Selye H. The Stress of Life. McGraw Hill, New York, 1956.

256. Serretti A., Lattuada E., Lorenzi C. et al. Dopamine receptor D2 Ser/Cys 311 variant is associated with delusion and disorganization symptomatology in major psychoses. Molecular Psychiatry 2000; 5: 270274.

257. Sharot T., Riccardi A.M., Raio C.M., Phelps E.A. Neural mechanisms mediating optimism bias. Nature 2007; publikacja internetowa z 24 pazdziernika (przed drukiem w kolejnym numerze pisma).

258. Shaw E.D., Mann J.J., Stokes P.E., Manevitz A.Z. Effects of lithium carbonate on associative productivity and idiosyncrasy in bipolar outpatients. American Journal of Psychiatry 1986; 143: 1166–1169.

259. Shorter E. The doctrine of the two depressions in historical perspective. Acta Psychiatrica Scandinavica 2007; 433: 5-13.

260. Skinner G.R., Hartley C., Buchan A. et al. The effect of lithium chloride on the replication of herpes simplex virus. Medical Microbiology and Immunology 1980; 168: 139–148.

261. Siowacki J. Anhelli. Universitas, Krakow, 2002.

262. Stuzewska A., Rybakowski J., Bosmans E. et al. Indicators of immune activation in major depression. Psychiatry Research 1996; 64: 161–167.

263. Soares J.C., Mallinger A.G. Intracellular phosphatidylinositol pathway abnormalities in bipolar disorder patients. Psychopharmacology Bulletin 1997; 33: 685–691.

264. Sophocles. Ajax. Cambridge University Press, Cambridge, 2001.

265. Starkstein S.E., Robinson R.G. Mechanism of disinhibition after brain lesions. Journal of Nervous and Mental Disease 1997; 185: 108–114.

266. Stevens A., Price J. Evolutionary Psychiatry: A New Beginning. Routledge, London, 1996.

267. Strakowski S.M., Adler C.M., DelBello M.P. Metabolic dysfunction within the anterior limbic network in bipolar disorder: a model for studying new treatments. Neuropsychiatria i Neu-ropsychologia 2006; 1: 5-14.

268. Strong C.M., Nowakowska C., Santosa C.M. et al. Temperament-creativity relationships in mood disorder patients, healthy controls and highly creative individuals. Journal of Affective Disorders 2007; 100: 41–48.

269. Strzyzewski W., Rybakowski J., Chtopocka-Wozniak M., Czerwinski A. Klozapina w leczeniu stanow maniakalnych. Psychiatria Polska 1981; 15: 331–332.

270. Styron W. Darkness Visible. A Memoir of Madness. Vintage Books, Newe York, 1991.

271. Swerdlow N.R., Stephany N, Wasserman LC et al. Dopamine agonists disrupt visual latent inhibition in normal males using a within-subject paradigm. Psychopharmacology (Berl) 2003; 169: 314–320.

272. Szadoczky E., Papp Z., Vitrai J. et al. The prevalence of major depressive and bipolar disorders in Hungary. Results from a national epidemiologic survey. Journal of Affective Disorders 1998; 50: 153–162.

273. Tellenbach H. Melancholie. Problemgeschichte, Endogenität, Typologie, Pathogenese, Klinik. Springer, Berlin, 1961.

274. The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993; 72: 971–983.

275. Tohen M., Baker R.W., Altshuler L.L. et al. Olanzapine versus divalproex in the treatment of acute mania. American Journal of Psychiatry 2002; 159: 1011–1017.

276. Tohen M., Chengappa K.N., Suppes T. et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabilizer v. mood stabilizer alone. British Journal of Psychiatry 2004; 184: 337–345.

277. Tohen M., Greil W., Calabrese J.R. et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. American Journal of Psychiatry 2005; 162: 1281–1290.

278. Tohen M., Vieta E., Calabrese J. et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Archives of General Psychiatry 2003; 60: 1079–1088.

279. Torrance E.P. Torrance Tests of Creative Thinking. Scholastic Testing Service, Bensenville, Illinois, 1990.

280. Vieta E. Improving treatment adherence in bipolar disorder through psychoeducation. Journal of Clinical Psychiatry 2005; 66 (Suppl 1): 2429.

281. Vornik L.A., Brown E.S. Management of comorbid bipolar disorder and substance abuse. Journal of Clinical Psychiatry 2006; 67 (Suppl 7): 2430.

282. Weiskrantz L. Behavioral changes associated with ablation of the amygdaloid complex in monkeys. Journal of Comparative Psychology and Physiology 1956; 49: 381–391.

283. Weissman M.M., Leaf P.J., Tischler G.L. et al. Affective disorders in five United States communities. Psychological Medicine 1988; 18: 141–153.

284. Welt L. Über Charakterveränderungen des Menschen infolge von Läsionen des Stirnhirns. Deutsches Archiv für klinische Medizin 1888; 42: 339–390.

285. Weygandt W. Über die Mischzustände des manisch-depressiven Irreseins. JF Lehmann, München, 1899.

286. Whybrow P.C. A Mood Apart. The Thinker’s Guide to Emotion and Its Disorders. Harper Perennial, New York, 1997.

287. Whybrow P.C. American mania. Ciągle więcej, ale nigdy dość. Termedia Wydawnictwo Medyczne, Poznań, 2006.

288. Whybrow P.C. American Mania. When More Is Not Enough. WW Norton & Company, New York – London, 2005.

289. Whybrow P.C, Akiskal H.S, McKinney W.T. Mood Disorders. Toward a New Psychobiology. Plenum Press, New York, 1984.

290. Whybrow P. Bahr R. The Hibernation Response. Arbor House, William Morrow, New York, 1988.

291. Whytt R. Observations on the Nature, Causes, and Cure of Those Disorders which have been Commonly Called Nervous, Hypochondriac, or Hysteric, to which are Prefixed Some Remarks on the Sympathy of the Nerves. T Becket and P DuHondt, London, and J Balfour, Edinburgh, 1765.

292. Wijeratne C., Malhi G.S. Vascular mania: an old concept in danger of sclerosing? A clinical overview. Acta Psychiatrica Scandinavica 2007; 434: 35–40.

293. Williams R.S., Cheng L., Mudge A.W., Harwood A.J. A common mechanism of action for three mood-stabilizing drugs. Nature 2002; 417: 292–295.

294. Wilson E.O. On Human Nature. Harvard University Press, Camridge, Massachusets, 2004.

295. Wise L.A, Zierler S., Krieger N., Harlow B.L. Adult onset of major depressive disorder in relation to early life violent victimisation: a case-control study. Lancet 2001; 358: 881–887.

296. Woody E., Claridge G. Psychoticism and thinking. British Journal of Social and Clinical Psychology 1977; 16: 241–248.

297. Wurtzel E. Prozac Nation. Young and Depressed in America. Quartet Books, London, 1996.

298. Zarate C.A. Is clozapine a mood stabilizer? Journal of Clinical Psychiatry 1995; 56: 108112.

299. Zarate C.A. Jr, Singh J.B., Carlson P.J. et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 2006; 63: 856–864.

300. Zarate C.A., Singh J.B., Carlson P.J et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disorders 2007; 9: 561–570.